Beyond Air, Inc. (XAIR)
After hours:
| Previous Close | 0.3949 |
| Open | 0.3831 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3819 - 0.4078 |
| 52 Week Range | 0.2960 - 2.6100 |
| Volume | |
| Avg. Volume | 542,354 |
| Market Cap | 28.744M |
| Beta (5Y Monthly) | -0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6400 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
GlobeNewswireBeyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Submitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants on Tuesday, November 5th at 9:00 AM U.S. ET Presentations of Beyond Cancer’s two full posters will take place on November 8th and 9th at the SITC Annual Meeting; ePublications of the posters will be available November 7th Therapeutic efficacy of Low Volume (<1L) UNO demonstrated in both mice and rat tumor models HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical
- GlobeNewswire
Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks
Revolutionary inhaled nitric oxide technology set to reach broader healthcare systemsGARDEN CITY, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced entering a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting fi
